(Circulation. 1995;92:987-993.)
© 1995 American Heart Association, Inc.
Articles |
From Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
Correspondence to Dr Peter Libby, Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Longwood Medical Research Center, Room 307, 221 Longwood Ave, Boston, MA 02115.
Background The relation between episodes of acute rejection and the development of graft coronary arteriosclerosis remains controversial. We examined the hypothesis that acute rejection episodes accelerate graft coronary arteriosclerosis lesion formation in rabbit allografts.
Methods and Results A control group (n=5) received cyclosporine 5 mg · kg-1 · d-1 for 6 weeks after heterotopic heart transplantation. In a rejection group (n=5), cyclosporine was omitted for 4 days at 1 and 4 weeks after transplantation. We studied cross sections of grafted hearts at 6 weeks and evaluated myocardial rejection grade, incidence, and severity and cell composition of intimal lesions in multiple coronary artery profiles. Episodic withdrawal of cyclosporine augmented myocardial rejection (International Society for Heart and Lung Transplantation grades 0, 0, 0, 0, and 1A in the control group to grades 1A, 1B, 2, 3A, and 3B in the rejection group). Episodes of acute rejection significantly increased the incidence (7.8±2.7% to 49.7±1.9%) and severity (from grade 0.10±0.04 to 0.79±0.24) of intimal thickening in graft coronary arteries. Most intimal lesions consisted of smooth muscle cells and contained various degrees of T-lymphocyte infiltration but sparse macrophages.
Conclusions In this experimental model, episodes of acute rejection precipitated by cyclosporine withdrawal accelerated the development of graft vascular lesion formation. Activation of vascular cells and leukocyte recruitment during acute rejection may thus contribute to the pathogenesis of graft arteriosclerosis.
Key Words: rejection arteritis cyclosporine transplantation arteriosclerosis
This article has been cited by other articles:
![]() |
J. C. Choy, A. Kerjner, B. W. Wong, B. M. McManus, and D. J. Granville Perforin Mediates Endothelial Cell Death and Resultant Transplant Vascular Disease in Cardiac Allografts Am. J. Pathol., July 1, 2004; 165(1): 127 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Y. Wang, I. Aronson, S. Takuma, S. Homma, Y. Naka, T. Alshafie, V. Brovkovych, T. Malinski, M. C. Oz, and D. J. Pinsky cAMP Pulse During Preservation Inhibits the Late Development of Cardiac Isograft and Allograft Vasculopathy Circ. Res., May 12, 2000; 86(9): 982 - 988. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-W. Hwang, A. Matsumori, Y. Furukawa, K. Ono, M. Okada, A. Iwasaki, M. Hara, and S. Sasayama FTY720, a New Immunosuppressant, Promotes Long-Term Graft Survival and Inhibits the Progression of Graft Coronary Artery Disease in a Murine Model of Cardiac Transplantation Circulation, September 21, 1999; 100(12): 1322 - 1329. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. O. Andersen, P. Holm, S. Stender, B. F. Hansen, and B. G. Nordestgaard Dose-Dependent Suppression of Transplant Arteriosclerosis in Aorta-Allografted, Cholesterol-Clamped Rabbits : Suppression Not Eliminated by the Cholesterol-Raising Effect of Cyclosporine Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2515 - 2523. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |